Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.
Bristol-Myers Squibb (BMS) has challenged the recently released report by the Institute for Clinical and Economic Review (ICER) that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma (MM). In a press release, the company said “We fundamentally disagree with ICER’s approach to value assessment, which led to the questionable conclusions outlined in its report.”
The company’s new treatment for MM, elotozumab (Empliciti), was 1 of 3 agents approved right before the annual meeting of the American Society of Hematology (ASH) in December 2015. Elotozumab, daratumumab (Darzalex), and ixazomib (Ninlaro) were all reviewed during a joint session held by the FDA and ASH. Left with multiple choices, how best can clinicians choose the treatment for their patients in combination with the standard of care?
The ICER report focused on 6 different combination treatments to be used as second or third-line treatments in relapsed/refractory patients with MM. However, the report concluded that while some of these combinations are promising, it’s too early to determine their cost-effectiveness.
BMS has raised objections to several sections of the report, with the patient perspective in mind:
3. It does not adhere to established Health Technology Assessment (HTA) best practices. HTA should be based on a clear, transparent, sophisticated and, differentiated view of value. It should include a clear understanding of disease management and indirect benefits.
“While assessments of cost-effectiveness may prove useful in comparing treatments, they have significant limitations, and the lack of available mature data sources preclude the drawing of valid conclusions,” the release claims.
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More